Coapt Systems, Inc.: Series E $22.6M

Coapt Systems (Palo Alto, CA) develops bio-absorbable implants for use in soft tissue fixation during facial cosmetic surgery procedures raised $22.6M in a Series E financing. The deal was led by Global Life Science Ventures and Easton Capital other participants included Alta Partners, Asset Management Company, Canaan Partners, Millennia Partners and Foundation Medical Partners.

Sanarus Medical, Inc: Series E $15M

Sanarus Medical (Pleasanton, CA) provides minimally invasive products for the diagnosis and treatment of breast tumors closed a $15M Series E round. The deal was led by Easton Capital Partners and Mosaix Ventures and were joined by U.S. Venture Partners, Forward Ventures, Alta Partners, Federated Kaufmann Fund, Pequot Ventures, Industry Ventures and Channel Medical Partners.

Sanarus Medical, Inc.: Series E $15M

Sanarus Medical (Pleasanton, CA) a biopsy device company focused on diagnosis and treatment of breast tumors raised $15M in Series E funding. Participants included Easton Capital Partners, Alta Partners, Forward Ventures, Channel Medical Partners, Federated Kaufman Fund, Pequot Private Equity and U.S. Venture Partners.

AlphaVax, Inc.: Series E $12.65M

AlphaVax (Durham, NC) a developer of vaccine products for infectious diseases (influenza & cytomegalovirus lead), biodefense and cancer, has raised approximately $12.65 million in Series E funding. Investors have not been disclosed.

Omeros, Inc.: Series E $63M

Omeros (Seattle, WA) a biopharmaceutical company focused on improving joint function following arthroscopic surgeries raised $63M in a Series E financing. Investors included Aravis Ventures, Arch Venture Partners, American Financial Group, Grosvenor Funds, Novartis Venture Fund, Southern Cross Capital, Stanley Medical Research Institute, and Trevi Health Ventures.

Fluidigm Corporation: Series E $37

Fluidigm Corporation (San Francisco) a producer of integrated fluidic circuits for the life sciences raised $37M in a Series E financing. The round was lead by Cross Creek Capital the private equity affiliate of Wasatch Advisors, Inc.